PharmaCyte Biotech, Inc. (PMCB)

PharmaCyte Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is May - April.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 31, 2025	Apr 30, 2025	Apr 30, 2024	Apr 30, 2023	Apr 30, 2022	Apr 30, 2021
Net Income	-1.13	30.66	0.33	-4.32	-4.24	-3.55
Stock-Based Compensation	0.32	0.48	0.67	0.65	0.11	0.44
Other Adjustments	-11.77	-35.47	-3.46	0.17	-	-0.08
Changes in Accounts Payable	-0.09	0.01	0.26	-0.24	0.03	-0.01
Changes in Accrued Expenses	0.36	1.31	0.19	-0.04	-0	-0.2
Changes in Other Operating Activities	0	0.04	-0.15	-0.01	-0.02	0.07
Operating Cash Flow	-4.6	-2.98	-2.15	-3.79	-4.12	-3.33
Purchases of Investments	-	-7	-5	-	-	-
Investing Cash Flow	-	-7	-5	-	-	-
Long-Term Debt Repaid	-	-	-	-	-0.05	-0.06
Net Long-Term Debt Issued (Repaid)	-	-	-	-	-0.05	-0.06
Issuance of Common Stock	-	-	0	0	87.36	4.7
Repurchase of Common Stock	-1.8	-2.54	-28.2	-13.56	-	-
Net Common Stock Issued (Repurchased)	-1.8	-2.54	-28.2	-13.56	87.36	4.7
Issuance of Preferred Stock	-	-	33.65	-	-	-
Repurchase of Preferred Stock	-	-22.49	-16.16	-	-	-
Net Preferred Stock Issued (Repurchased)	-	-22.49	17.49	-	-	-
Financing Cash Flow	-14.86	-25.03	-10.71	-13.56	87.31	4.64
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-0	-0	-0	-0.01	0	0
Net Cash Flow	-19.46	-35.01	-17.86	-17.36	83.2	1.31
Beginning Cash & Cash Equivalents	32.64	50.18	68.04	85.4	2.2	0.89
Ending Cash & Cash Equivalents	13.18	15.17	50.18	68.04	85.4	2.2
Free Cash Flow	-4.6	-2.98	-2.15	-3.79	-4.12	-3.33
Free Cash Flow Per Share	-0.65	-0.41	-0.22	-0.19	-0.27	-2.30
Levered Free Cash Flow	-5.31	24.72	-16.94	-4.61	-4.28	-3.76
Unlevered Free Cash Flow	-3.68	-3.02	-8.22	-6.75	-4.38	-3.77

Updated Sep 15, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q